The Oxalosis & Hyperoxaluria Foundation disburses grants and funding to researchers who study the causes of hyperoxaluria and its treatment. Please visit our OHF Grants Funded page to explore the impact of these initiatives and researchers.
Application deadline: December 15, 2022 at midnight ET
The OHF seeks to support research that will ultimately lead to new diagnostics, treatments, and a cure for primary hyperoxaluria and related hyperoxaluria conditions.
Short-term travel grant
Application deadline: Open
The OHF’s short-term travel grant supports postdoctoral and mid-career researchers to receive hands-on training for up to 3 months in advanced host institutions or laboratories.
The ultimate goal is to improve the standards in each recipient’s home institution upon their return, which will help them become leaders in their fields.
Researchers receive hands-on training in outside laboratories, allowing them to acquire state-of-the-art knowledge of a new technique, methodology, or philosophical approach that would complement their own knowledge and experience and enhance their ability to carry out high-quality research compatible with the mission of the OHF.
OHF global registry initiative
Application deadline: Open
We are seeking proposals to develop international collaborative patient registries and databases to identify the determinants of the clinical manifestations and prognosis of patients with primary hyperoxaluria.
As part of its wider mission to improve the understanding and treatment of primary hyperoxaluria and related calcium oxalate kidney stone diseases, the Oxalosis & Hyperoxaluria Foundation is interested in receiving proposals from scientists and clinicians that address the issue of the influence of genetic, cultural, and environmental background on the clinical manifestations and prognosis of patients with primary hyperoxaluria. To this end, financial support will be given to international collaborative projects that develop and make use of well- defined patient cohorts covering a wide range of genetic and cultural backgrounds.
Possible questions to be addressed include, but are not limited to:
- The influence of urinary oxalate level and other urine parameters on renal outcomes.
- The influence of dietary intake on urinary oxalate level and renal outcomes.
- Genotype-phenotype correlations within and between primary hyperoxaluria types.
In countries where no such databases exist, the OHF is willing to provide funding to help local clinicians and scientists to organize collections of primary hyperoxaluria patient information into standardized registries and databases and to make this information available for approved research projects that address the issues above. A required element of a successful response to this proposal will be a detailed data-sharing plan for key data elements that are collected under this program.
Proposed timelines can be 1 to 2 years; however, additional funds will be available for registry maintenance to sites that achieve predefined benchmarks (eg, patient enrollment targets) in the first year. Successful proposals will benefit clinicians in treating primary hyperoxaluria patients and provide a framework for the evaluation of existing and potential new therapies.
Primary hyperoxaluria type 3 grant
Application deadline: Closed
Of the known genetic causes of primary hyperoxaluria, PH type 3 is the most recently identified and now known to be caused by mutations in the HOGA1 gene. Although the causative gene is known we still lack much basic information regarding this disease. Indeed, it is not entirely clear how mutations in this gene cause hyperoxaluria. It is not clear what the natural history is of this disorder or if there are treatment approaches that might be uniquely beneficial for PH3 over PH types 1 and 2.
To fill these gaps, the OHF specifically seeks funding applications to study PH type 3. Applications could be clinical, translational, or basic science in focus. Possible areas of study include, but are not limited to, the mechanism(s) of hyperoxaluria, novel treatment strategies and targets, novel biomarkers, and new information regarding risk factors for stone formation or chronic kidney disease in PH type 3.
OHF will award up to $200,000 total for up to 2 years. Indirect costs must be included in the maximum funding amount.